Notícias e Atividades da Helsinn Healthcare
Executivos
Veja o organograma con seus 15 executivos principais
Biografias mais buscadas da Helsinn Healthcare
- Riccardo Braglia, Chief Executive Officer
- Paolo Bottini, Board Member
- Riccardo Carbucicchio, Executive Chairman of the Board
Recentes movimentos de executivos em Helsinn Healthcare
- Melanie Rolli, Group Chief Executive Officer, deixou a Companhia (Notícia publicada em 13 de janeiro de 2026).
- Gabriele Braglia antes Director, foi promovido a Chief Business Officer and Deputy Chief Executive Officer (Notícia publicada em 13 de janeiro de 2026).
- Riccardo Braglia antes Board Member, foi promovido a Chief Executive Officer (Notícia publicada em 13 de janeiro de 2026).
Criar um alerta
para seguir os movimentos de executivos da Helsinn Healthcare.
Farmacêutica
Helsinn Healthcare possui 1.913 concorrentes concorrentes Sanofi (França), Eli Lilly (Estados Unidos) e Moderna (Estados Unidos).
Popular M&A news in Farmacêutica
- Corden Pharma has announced the acquisition of AmbioPharm (publicado em 5 de junho de 2026).
- Laboratoire Servier has announced the acquisition of Edgewise Therapeutics (publicado em 4 de junho de 2026).
- Contraline acaba de anunciar uma arrecadação de fundos de 93 milhões de dólares. (publicado em 3 de junho de 2026).
Outros contatos sugeridos na indústria do Farmacêutica
Notícias
Últimos comunicados de imprensa de Helsinn Healthcare
- News - Helsinn
- News and Events - Helsinn
- https://www.helsinn.com/news-and-events/taiho-pharmaceutical-submits-new-drug-application-for-nk1-receptor-antagonist-fosnetupitant-for-prevention-of-gastrointestinal-symptoms-nausea-and-vomiting-associated-with-cancer-chemotherapy/
- https://www.helsinn.com/news-and-events/helsinn-publishes-prove-mf-ctcl-study-providing-new-data-for-mechlorethamine-gel-use-in-a-real-world-setting/
- Helsinn announces publication of latest mechlorethamine gel research, highlighting its efficacy and safety
- https://www.helsinn.com/news-and-events/announcement-of-approval-to-manufacture-and-market-5-ht3-serotonin-receptor-antagonist-antiemetic-agent-palonosetron-i-v-injection-palonosetron-i-v-infusion-bag-in-japan/
- ONO Receives a Manufacturing and Marketing Approval of Adlumiz® (Anamorelin), a Ghrelin Receptor Agonist for the Treatment of Cancer Cachexia in Japan
- An interview with Dr. Larisa Geskin on an MF-CTCL fellowship at Columbia University supported by Helsinn
- Helsinn Announces First Patient Dosed in Phase 1/2 Study of TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities
- https://www.helsinn.com/news-and-events/helsinn-demonstrates-commitment-to-raising-awareness-on-cachexia-by-supporting-cachexia-societies-conferences/
- View more press releases Close
Redes sociais sobre Helsinn Healthcare
- Helsinn Healthcare na Wikipedia, Google News e Yahoo Finance
- Helsinn Healthcare na LinkedIn, X (Twitter) e YouTube
